Images from European Biotech and Pharma Partnering Conference in Osaka, Japan 2016


Leave a comment

bioXclusters reinforces its pathways to the Japanese market

Japan is the second largest pharmaceutical market in the world and leader in imports of the sector. Japanese life sciences companies are in the process of globalization and need alliances with foreign companies and biotechnology institutions to develop new medicines and incorporate new technologies. To that end, Japan is a strategic market for bioXclusters metacluster alliance. In collaboration with its Japanese Gateway Osaka Bio Headquarters, and with support of the EU-Japan Centre for industrial collaboration, bioXclusters organizes a mission to Japan in October 2017, following the 2016 success.

The organized mission allows to attend the following events. 

  • BioJapan (11-13 October 2017): Asia-wide benchmark trade fair for the global biotechnology industry that will bring together key business development and licensing professionals, R&D professionals and executives from biotechnology companies. This year’s fair also includes a HealthCare management and digital health area.

Aforementioned European Biotech and Pharma Partnering Conference in Osaka offers business contacts to industry professionals who are looking for Continue reading

Advertisements


Leave a comment

Call for Mission to China with bioXclusters

The bioXclusters project partners are planning a trade mission to Shanghai (China) to learn mor about the life sciences sector in this country. The mission will take place from the 26th to the 31st May 2013 and plans to attend two events.  All partners in the project as well as some companies located in the bioXcluster regions will take part in this mission. Continue reading


Leave a comment

Things you have to know about Regulatory Issues in China

There’s no question that China is an appealing market for the biotech industry. This is not only because of the possibilities it offers for lowering  R&D costs, but also because of its market size. Demographics are a reason for this country’s attractiveness: a large and progressively wealthier population that is getting older represents a  new market of potential users of biotech products.

But investing in China is not an easy process. The lack of transparency and the challenges related to regulatory issues make the process long and difficult, in addition to the maze of authorities involved. Continue reading